Receptor Tyrosine Protein Kinase ERBB 3 Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL RECEPTOR TYROSINE PROTEIN KINASE ERBB 3 INDUSTRY

2.1 Summary about Receptor Tyrosine Protein Kinase ERBB 3 Industry

2.2 Receptor Tyrosine Protein Kinase ERBB 3 Market Trends

2.2.1 Receptor Tyrosine Protein Kinase ERBB 3 Production & Consumption Trends

2.2.2 Receptor Tyrosine Protein Kinase ERBB 3 Demand Structure Trends

2.3 Receptor Tyrosine Protein Kinase ERBB 3 Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 BA-0702

4.2.2 CDX-3379

4.2.3 Elgemtumab

4.2.4 ETBX-031

4.2.5 Others

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Non-Small Cell Carcinoma

4.3.2 Solid Tumor

4.3.3 Melanoma

4.3.4 Colorectal Cancer

4.3.5 Others

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 BA-0702

5.2.2 CDX-3379

5.2.3 Elgemtumab

5.2.4 ETBX-031

5.2.5 Others

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Non-Small Cell Carcinoma

5.3.2 Solid Tumor

5.3.3 Melanoma

5.3.4 Colorectal Cancer

5.3.5 Others

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 BA-0702

6.2.2 CDX-3379

6.2.3 Elgemtumab

6.2.4 ETBX-031

6.2.5 Others

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Non-Small Cell Carcinoma

6.3.2 Solid Tumor

6.3.3 Melanoma

6.3.4 Colorectal Cancer

6.3.5 Others

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 BA-0702

7.2.2 CDX-3379

7.2.3 Elgemtumab

7.2.4 ETBX-031

7.2.5 Others

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Non-Small Cell Carcinoma

7.3.2 Solid Tumor

7.3.3 Melanoma

7.3.4 Colorectal Cancer

7.3.5 Others

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 BA-0702

8.2.2 CDX-3379

8.2.3 Elgemtumab

8.2.4 ETBX-031

8.2.5 Others

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Non-Small Cell Carcinoma

8.3.2 Solid Tumor

8.3.3 Melanoma

8.3.4 Colorectal Cancer

8.3.5 Others

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 BA-0702

9.2.2 CDX-3379

9.2.3 Elgemtumab

9.2.4 ETBX-031

9.2.5 Others

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Non-Small Cell Carcinoma

9.3.2 Solid Tumor

9.3.3 Melanoma

9.3.4 Colorectal Cancer

9.3.5 Others

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 AstraZeneca Plc

10.1.2 AVEO Pharmaceuticals, Inc.

10.1.3 Etubics Corporation

10.1.4 F. Hoffmann-La Roche Ltd.

10.1.5 GamaMabs Pharma S.A.

10.1.6 GlaxoSmithKline Plc

10.1.7 Hanmi Pharmaceuticals, Co. Ltd.

10.1.8 ImmunoGen, Inc.

10.1.9 Kolltan Pharmaceuticals, Inc.

10.1.10 Merrimack Pharmaceuticals, Inc.

10.1.11 Merus B.V.

10.1.12 Novartis AG

10.1.13 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

10.1.14 Sihuan Pharmaceutical Holdings Group Ltd.

10.1.15 Sorrento Therapeutics, Inc.

10.1.16 Symphogen A/S

10.1.17 Takis S.r.l.

10.2 Receptor Tyrosine Protein Kinase ERBB 3 Sales Date of Major Players (2017-2020e)

10.2.1 AstraZeneca Plc

10.2.2 AVEO Pharmaceuticals, Inc.

10.2.3 Etubics Corporation

10.2.4 F. Hoffmann-La Roche Ltd.

10.2.5 GamaMabs Pharma S.A.

10.2.6 GlaxoSmithKline Plc

10.2.7 Hanmi Pharmaceuticals, Co. Ltd.

10.2.8 ImmunoGen, Inc.

10.2.9 Kolltan Pharmaceuticals, Inc.

10.2.10 Merrimack Pharmaceuticals, Inc.

10.2.11 Merus B.V.

10.2.12 Novartis AG

10.2.13 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

10.2.14 Sihuan Pharmaceutical Holdings Group Ltd.

10.2.15 Sorrento Therapeutics, Inc.

10.2.16 Symphogen A/S

10.2.17 Takis S.r.l.

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

Table Receptor Tyrosine Protein Kinase ERBB 3 Product Type Overview

Table Receptor Tyrosine Protein Kinase ERBB 3 Product Type Market Share List

Table Receptor Tyrosine Protein Kinase ERBB 3 Product Type of Major Players

Table Brief Introduction of AstraZeneca Plc

Table Brief Introduction of AVEO Pharmaceuticals, Inc.

Table Brief Introduction of Etubics Corporation

Table Brief Introduction of F. Hoffmann-La Roche Ltd.

Table Brief Introduction of GamaMabs Pharma S.A.

Table Brief Introduction of GlaxoSmithKline Plc

Table Brief Introduction of Hanmi Pharmaceuticals, Co. Ltd.

Table Brief Introduction of ImmunoGen, Inc.

Table Brief Introduction of Kolltan Pharmaceuticals, Inc.

Table Brief Introduction of Merrimack Pharmaceuticals, Inc.

Table Brief Introduction of Merus B.V.

Table Brief Introduction of Novartis AG

Table Brief Introduction of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Table Brief Introduction of Sihuan Pharmaceutical Holdings Group Ltd.

Table Brief Introduction of Sorrento Therapeutics, Inc.

Table Brief Introduction of Symphogen A/S

Table Brief Introduction of Takis S.r.l.

Table Products & Services of AstraZeneca Plc

Table Products & Services of AVEO Pharmaceuticals, Inc.

Table Products & Services of Etubics Corporation

Table Products & Services of F. Hoffmann-La Roche Ltd.

Table Products & Services of GamaMabs Pharma S.A.

Table Products & Services of GlaxoSmithKline Plc

Table Products & Services of Hanmi Pharmaceuticals, Co. Ltd.

Table Products & Services of ImmunoGen, Inc.

Table Products & Services of Kolltan Pharmaceuticals, Inc.

Table Products & Services of Merrimack Pharmaceuticals, Inc.

Table Products & Services of Merus B.V.

Table Products & Services of Novartis AG

Table Products & Services of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Table Products & Services of Sihuan Pharmaceutical Holdings Group Ltd.

Table Products & Services of Sorrento Therapeutics, Inc.

Table Products & Services of Symphogen A/S

Table Products & Services of Takis S.r.l.

Table Market Distribution of Major Players

Table Global Major Players Sales Revenue (Million USD) 2017-2020e

Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

Table Global Receptor Tyrosine Protein Kinase ERBB 3 Market Forecast (Million USD) by Region 2021f-2026f

Table Global Receptor Tyrosine Protein Kinase ERBB 3 Market Forecast (Million USD) Share by Region 2021f-2026f

Table Global Receptor Tyrosine Protein Kinase ERBB 3 Market Forecast (Million USD) by Demand 2021f-2026f

Table Global Receptor Tyrosine Protein Kinase ERBB 3 Market Forecast (Million USD) Share by Demand 2021f-2026f